Clinical outcomes of patients according to opioid use at baseline, other than codeine or dihydrocodeine, over 12-month longitudinal follow-up.
| . | Using Opioids at Baseline (n = 39) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 6 (15.4) | 139 (15.2) | .98 | 1.08 (0.48–2.45) | .85 | 0.83 (0.27–2.58) | .74 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 1 (2.6) | 66 (7.2) | .27 | 0.36 (0.05–2.61) | .31 | 0.32 (0.04–2.86) | .31 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 3 (7.7) | 117 (12.8) | .35 | 0.61 (0.19–1.91) | .39 | 0.51 (0.11–2.31) | .38 |
| Hospitalization due to uncontrolled IBD activity (%) | 4 (10.3) | 31 (3.4) | .026 | 3.23 (1.14–9.15) | .027 | 5.08 (1.12–23.0) | .035 |
| Intestinal resection due to uncontrolled IBD activity (%) | 3 (7.7) | 11 (1.2) | .001 | 6.75 (1.88–24.2) | .003 | 42.9 (3.36–548) | .004 |
| Any of the above (%) | 8 (20.5) | 165 (18.1) | .70 | 1.21 (0.60–2.47) | .60 | 0.96 (0.35–2.66) | .94 |
| . | Using Opioids at Baseline (n = 39) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 6 (15.4) | 139 (15.2) | .98 | 1.08 (0.48–2.45) | .85 | 0.83 (0.27–2.58) | .74 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 1 (2.6) | 66 (7.2) | .27 | 0.36 (0.05–2.61) | .31 | 0.32 (0.04–2.86) | .31 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 3 (7.7) | 117 (12.8) | .35 | 0.61 (0.19–1.91) | .39 | 0.51 (0.11–2.31) | .38 |
| Hospitalization due to uncontrolled IBD activity (%) | 4 (10.3) | 31 (3.4) | .026 | 3.23 (1.14–9.15) | .027 | 5.08 (1.12–23.0) | .035 |
| Intestinal resection due to uncontrolled IBD activity (%) | 3 (7.7) | 11 (1.2) | .001 | 6.75 (1.88–24.2) | .003 | 42.9 (3.36–548) | .004 |
| Any of the above (%) | 8 (20.5) | 165 (18.1) | .70 | 1.21 (0.60–2.47) | .60 | 0.96 (0.35–2.66) | .94 |
aχ2 for comparison of data between groups.
Clinical outcomes of patients according to opioid use at baseline, other than codeine or dihydrocodeine, over 12-month longitudinal follow-up.
| . | Using Opioids at Baseline (n = 39) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 6 (15.4) | 139 (15.2) | .98 | 1.08 (0.48–2.45) | .85 | 0.83 (0.27–2.58) | .74 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 1 (2.6) | 66 (7.2) | .27 | 0.36 (0.05–2.61) | .31 | 0.32 (0.04–2.86) | .31 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 3 (7.7) | 117 (12.8) | .35 | 0.61 (0.19–1.91) | .39 | 0.51 (0.11–2.31) | .38 |
| Hospitalization due to uncontrolled IBD activity (%) | 4 (10.3) | 31 (3.4) | .026 | 3.23 (1.14–9.15) | .027 | 5.08 (1.12–23.0) | .035 |
| Intestinal resection due to uncontrolled IBD activity (%) | 3 (7.7) | 11 (1.2) | .001 | 6.75 (1.88–24.2) | .003 | 42.9 (3.36–548) | .004 |
| Any of the above (%) | 8 (20.5) | 165 (18.1) | .70 | 1.21 (0.60–2.47) | .60 | 0.96 (0.35–2.66) | .94 |
| . | Using Opioids at Baseline (n = 39) . | Not Using Opioids at Baseline (n = 913) . | P . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| Flare of disease activity (%) | 6 (15.4) | 139 (15.2) | .98 | 1.08 (0.48–2.45) | .85 | 0.83 (0.27–2.58) | .74 |
| Glucocorticosteroid prescription due to uncontrolled IBD activity (%) | 1 (2.6) | 66 (7.2) | .27 | 0.36 (0.05–2.61) | .31 | 0.32 (0.04–2.86) | .31 |
| Escalation of IBD therapy due to uncontrolled IBD activity (%) | 3 (7.7) | 117 (12.8) | .35 | 0.61 (0.19–1.91) | .39 | 0.51 (0.11–2.31) | .38 |
| Hospitalization due to uncontrolled IBD activity (%) | 4 (10.3) | 31 (3.4) | .026 | 3.23 (1.14–9.15) | .027 | 5.08 (1.12–23.0) | .035 |
| Intestinal resection due to uncontrolled IBD activity (%) | 3 (7.7) | 11 (1.2) | .001 | 6.75 (1.88–24.2) | .003 | 42.9 (3.36–548) | .004 |
| Any of the above (%) | 8 (20.5) | 165 (18.1) | .70 | 1.21 (0.60–2.47) | .60 | 0.96 (0.35–2.66) | .94 |
aχ2 for comparison of data between groups.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
